You are here

  • Home
  • Archive
  • Volume 13, Issue 9
  • Microsatellite instability driven metastatic parathyroid carcinoma managed with the anti-PD1 immunotherapy, pembrolizumab

Article Text

Article menu
Download PDFPDF
Novel treatment (new drug/intervention; established drug/procedure in new situation)
Case report
Microsatellite instability driven metastatic parathyroid carcinoma managed with the anti-PD1 immunotherapy, pembrolizumab
  1. Daniel Park1,
  2. Rany Airi1 and
  3. Michael Sherman2
  1. 1Internal Medicine, Touro University California, Vallejo, California, USA
  2. 2Hematolgy & Oncology, Contra Costa Oncology, Walnut Creek, California, USA
  1. Correspondence to Daniel Park; Daniel.park2{at}tu.edu

Abstract

The present case report describes a 65-year-old man with Lynch syndrome and hypercalcaemia associated with hyperparathyroidism. Parathyroid surgery confirmed the diagnosis of parathyroid carcinoma. Serum calcium and parathyroid hormone (PTH) concentrations serially increased after initial surgery. Imaging study and subsequent biopsy confirmed lung metastases with mismatch repair deficiency. Pembrolizumab was initiated achieving 60% reduction in tumour burden.

  • oncology
  • cancer intervention

https://doi.org/10.1136/bcr-2020-235293

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors DP: medical student, drafted the case report; RA: medical student, assisted with literature review and revisions; MS: attending physician who determined treatment plan and management.

    • Funding This study was funded Touro University California (grant number: 652158).

    • Competing interests None declared.

    • Patient consent for publication Obtained.

    • Provenance and peer review Not commissioned; externally peer reviewed.